MedTrace Logo

Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors

NCT02678780 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 123

Last updated 2025-07-24

Study results available
· View outcomes & findings →

Summary

This is a prospective, international, multi-center, open label, stratified, exploratory phase II study evaluating the efficacy and safety of lenvatinib in patients with advanced/metastatic, neuroendocrine tumors of the pancreas after progression to a previous targeted agent (cohort A) or gastrointestinal tract after progression to somatostatin analogues (cohort B).

Conditions

Interventions

DRUG

Lenvatinib

Sponsors & Collaborators

  • Eisai Limited

    collaborator INDUSTRY

  • Experior S.L.

    collaborator UNKNOWN

  • Grupo Espanol de Tumores Neuroendocrinos

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2017-12-31
Completion
2020-08-31

Countries

  • Austria
  • Italy
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02678780 on ClinicalTrials.gov